On Apr 11, 2019 EASTON PHARMACEUTICALS INC (OTCMKTS:EAPH) Sellers Rose Their Shorts By 249.23%

Easton Pharmaceuticals Inc. (OTCMKTS:EAPH) Corporate Logo

EASTON PHARMACEUTICALS INC (OTCMKTS:EAPH) recorded an increase of 249.23% in shorted shares. In April was published EAPH’s total 90,800 shorted shares by FINRA. That’s 249.23% up from 26,000 shares.

EAPH is hitting $0.0099 during the last trading session, after increased 3.12%.Currently Easton Pharmaceuticals Inc. is after 0.00% change in last April 11, 2018. EAPH has 1.66 million shares volume. The stock underperformed the S&P 500 by 4.37%.

Easton Pharmaceuticals Inc., a specialty pharmaceutical company, designs, develops, and markets various topically delivered drugs and therapeutic health care products.The firm is valued at $12.43 million. The Company’s products include Nauseasol, a motion sickness gel; Skin Renou HA, an anti-aging wrinkle cream using hyaluronic acid, which keeps the skin smooth; Kenestrin Gel used for arthritis, knees, elbows, shoulders, wrist, and back pain; Viorra, a hormone free, non-toxic, and topical gel that improves sexual functioning of women; and female sexual arousal disorder drug.Currently it has negative earnings. The firm is also developing XILIVE, an early stage cancer drug.

For more Easton Pharmaceuticals Inc. (OTCMKTS:EAPH) news posted recently go to: Investorplace.com, Seekingalpha.com, Seekingalpha.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “10 Marijuana Stocks for the Canadian ‘Pot Rush’ – Investorplace.com” posted on October 17, 2018, “Canada’s Marijuana Market: The Good, Bad, And Ugly – Seeking Alpha” on December 31, 2014, “Medical marijuana now legal in Thailand – Seeking Alpha” with a publish date: December 25, 2018, “GMP Securities outlines opportunities in U.S. cannabis – Seeking Alpha” and the last “Largest U.S. cannabis company listed on Canadian exchange – Seeking Alpha” with publication date: May 29, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.